Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

Inclusion criteria for those with hepatic impairment: * Physical signs consistent with a clinical diagnosis of liver cirrhosis * Child-Pugh Clinical Assessment Score consistent with degree of hepatic impairment * Otherwise considered healthy Inclusion criteria for healthy volunteers: • In good health. Exclusion criteria for those with hepatic impairment: * Clinically significant abnormal findings other than hepatic impairment * Clinical evidence of severe ascites * History of surgical portosystemic shunt * Any evidence of progressive liver disease within the last 4 weeks Exclusion criteria for healthy controls: * Clinical evidence of liver disease or liver injury * A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result * Use of any prescription medication within 1 month prior to dosing Other protocol defined inclusion/exclusion criteria may apply.